Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics Inc (NQ: ARQT )

19.09 +0.79 (+4.32%)
Streaming Delayed Price Updated: 3:51 PM EDT, Sep 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 487,230
Open 18.35
Bid (Size) 19.07 (6)
Ask (Size) 19.10 (4)
Prev. Close 18.30
Today's Range 18.35 - 19.46
52wk Range 13.59 - 27.40
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga

Performance

YTD
-16.24%
-16.24%
1 Month
-21.86%
-21.86%
3 Month
-13.35%
-13.35%
6 Month
+3.47%
+3.47%
1 Year
-17.75%
-17.75%

More News

Read More
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
Via Benzinga
Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Via Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Arcutis Concludes Dosing In Late-Stage Itchy Skin Study, Anticipates Regulatory Submission By Next Year
Via Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Via Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
Via Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Analyst Ratings for Arcutis Biotherapeutics
Via Benzinga
Why Revlon Shares Jumped 90%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial
Via Benzinga
Recap Of Friday's Biotech Catalysts - End of The Day Summary
Via Benzinga
Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August
Via Benzinga
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update
Via Benzinga
7 Biotech Stocks to Buy for Q3
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
Via Benzinga
Mizuho Sees Buying Opportunity Despite Weakness In This Skin-Disease Focused Stock
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
88 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.